ARK trims Meta and Roku

In a fresh round of ARK Invest trades, Cathie Wood rebalanced several flagship ETFs by cutting exposure to big tech and adding to a high-conviction healthcare AI name.

ARK cuts Meta position after trial and layoffs

Cathie Wood‘s ARK Invest trimmed its Meta position on Wednesday, March 25, redirecting capital toward healthcare-focused artificial intelligence. However, the move came as Meta faced both legal and operational headwinds in the United States.

Across three funds, ARK sold 3,578 Meta shares, worth about $2.1 million based on the stock’s closing price. Moreover, after this sale, the ARK Innovation ETF now holds roughly 105,000 Meta shares valued at close to $63 million, representing about 1% of the fund.

A jury found Meta and Google’s YouTube negligent in a landmark social-media addiction trial, ruling that their products harmed children and teenagers. Both companies said they plan to appeal. That said, Meta also introduced a new executive pay plan targeting a 500% stock increase and a potential $9 trillion valuation by 2031.

The company confirmed to Barron’s that it was laying off several hundred employees across its sales, recruiting, and virtual reality divisions. However, despite the legal setback and layoffs, Meta shares ended the day up just 0.3%, signaling limited immediate market reaction.

ARK trims Roku and other technology names

Alongside Meta, ARK further cut its exposure to Roku. The firm sold 95,090 Roku shares across its ARKK, ARKW, and ARKF funds, for a total of around $9.1 million. Moreover, this move followed a sizable Roku sale the previous day, on March 24.

Other significant sales included 30,174 shares of Teradyne for roughly $9.7 million, reflecting further de-risking in hardware and testing names. ARK also sold 205,019 shares of Bullish across three ETFs, worth about $7.7 million. The firm has been selling Bullish consistently over the past week, signaling a clear rotation away from that holding.

Additional disposals on Wednesday featured 62,393 shares of Kratos Defense at approximately $4.8 million in value, and 27,647 shares of Natera worth about $5.4 million. That said, ARK’s overall strategy appears less about broad risk-off positioning and more about reallocating capital into targeted growth themes.

ARK’s big bet on Tempus AI

On the buying side, Tempus AI dominated the day’s transactions. ARK purchased 84,939 Tempus AI shares through its ARKK and ARKG ETFs, spending around $4.1 million. However, the new allocation came even as the stock remained under pressure in public markets.

Tempus AI fell 4.2% on Wednesday and is down 21% so far in 2026, making ARK’s move look like a deliberate dip-buy. Moreover, ARK Innovation ETF now holds around 6.3 million Tempus AI shares worth more than $294 million, turning the company into one of its highest-conviction positions.

That makes Tempus AI the fund’s third-largest holding, behind Tesla and Crispr Therapeutics, accounting for roughly 5% of the total portfolio. This size clearly underscores Wood’s focus on healthcare AI as a long-term disruptive theme rather than a short-term trade.

Why ARK is leaning into healthcare AI

Tempus AI is a healthcare technology company that uses artificial intelligence to manage and interpret medical data, with a particular focus on cancer care. However, unlike pure software plays, its model sits at the intersection of data infrastructure, diagnostics, and clinical decision support.

Strategically, this push into healthcare AI aligns with ARK’s thesis that genomic and data-driven medicine will unlock substantial value over the next decade. Moreover, concentrating capital in Tempus AI while trimming legacy internet and streaming names signals a pivot toward what Wood sees as the next major growth cycle.

A pattern in recent ark invest trades

Recent transaction data shows that ark invest trades are part of a broader pattern rather than isolated moves. Over several consecutive days, ARK has been reducing positions in Roku, Teradyne, and Bullish while steadily building its stake in Tempus AI. That said, the firm is not abandoning other innovation themes entirely.

Smaller purchases on Wednesday included shares of Archer Aviation, Beam Therapeutics, and several other high-growth names. Moreover, the ARK Innovation ETF itself closed the day up 1.3%, suggesting investors remain confident in Wood’s long-term disruptive innovation strategy despite significant portfolio churn.

In summary, ARK’s latest rebalancing on March 25 shows a clear rotation away from social-media and streaming stocks toward healthcare-focused artificial intelligence, with Tempus AI emerging as a central pillar of the firm’s 2026 innovation bet.